prikaz prve stranice dokumenta Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms
  Download
PDF 242.87 KB
Scientific paper - Other
Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms
Diabetology, 4 (2023), 3; 251-258. https://doi.org/10.3390/diabetology4030022
Belančić, Andrej; Klobučar, Sanja

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Belančić, A. & Klobučar, S. (2023). Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms. Diabetology, 4. (3), 251-258. doi: 10.3390/diabetology4030022

Belančić, Andrej and Sanja Klobučar. "Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms." Diabetology, vol. 4, no. 3, 2023, pp. 251-258. https://doi.org/10.3390/diabetology4030022

Belančić, Andrej and Sanja Klobučar. "Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms." Diabetology 4, no. 3 (2023): 251-258. https://doi.org/10.3390/diabetology4030022

Belančić, A. and Klobučar, S. (2023) 'Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms', Diabetology, 4(3), pp. 251-258. doi: 10.3390/diabetology4030022

Belančić A, Klobučar S. Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms. Diabetology [Internet]. 2023 July 04 [cited 2024 December 27];4(3):251-258. doi: 10.3390/diabetology4030022

A. Belančić and S. Klobučar, "Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms", Diabetology, vol. 4, no. 3, pp. 251-258, July 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:874312. [Accessed: 27 December 2024]

Metadata
Title (english)Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms
AuthorAndrej Belančić
AuthorSanja Klobučar
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been linked to beneficial effects on cardiovascular risk factors, blood pressure, body weight, and lipid profile, according to a substantial body of literature. Significant cardiac and renal benefits with the use of SGLT2 inhibitors have been shown in patients with type 2 diabetes, as well as in those with heart failure and/or chronic kidney disease (CKD), regardless of diabetes status, in subsequent large cardiovascular outcome trials. Thus, SGLT2 inhibitors have become a mainstay of therapy for type 2 diabetes in patients with established cardiovascular disease and CKD due to their benefits for the heart and kidneys. Based on data from randomized controlled trials and meta-analyses, this article attempts to present a thorough review of the mechanism of action, as well as the benefits of SGLT2 inhibitors for cardiac and renal protection. On the basis of a growing body of literature on diabetes and other conditions, clinical practice guidelines have been updated to suggest the use of SGLT2 inhibitors in specific patient populations. These modifications will also be concisely described, based on evidence-based medicine principles.
Keywords (english)
Languageenglish
Publication typeScientific paper - Other
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDiabetology
Numberingvol. 4, no. 3, pp. 251-258
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology4030022
URN:NBNurn:nbn:hr:184:874312
Publication2023-07-04
Document URLhttps://www.mdpi.com/2673-4540/4/3/22
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-07-10 12:52:28